Department of Hematology, Juntendo University Urayasu Hospital, Japan.
Department of Neurosurgery, Juntendo University Urayasu Hospital, Japan.
Intern Med. 2023 Feb 1;62(3):459-463. doi: 10.2169/internalmedicine.9591-22. Epub 2022 Jul 5.
Many patients with primary vitreoretinal lymphoma (PVRL) exhibit central nervous system (CNS) involvement either at the diagnosis or during follow-up. The prognosis in the patients of PVRL with relapsed or refractory CNS remains extremely poor. We herein report a patient with refractory PVRL who had recurrence in the spinal cord despite receiving high-dose methotrexate-based chemotherapy and whole-brain radiotherapy. The patient surprisingly responded to tirabrutinib temporarily. We believe that this case suggests the utility of this new target therapy.
许多原发性眼内淋巴瘤(PVRL)患者在诊断时或随访期间存在中枢神经系统(CNS)受累。复发或难治性 CNS 原发性眼内淋巴瘤患者的预后仍然极差。我们在此报告一例难治性 PVRL 患者,尽管接受了大剂量甲氨蝶呤为基础的化疗和全脑放疗,但脊髓仍复发。该患者出人意料地对替拉鲁替尼暂时有反应。我们认为该病例提示了这种新的靶向治疗的有效性。